The IL18 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung carcinoma cell line, featuring disruption of the IL18 gene to establish a loss-of-function model. This polyclonal pool avoids clonal selection bias, preserving genetic diversity and minimizing clone-specific artifacts, suitable for population-level analyses of IL18-dependent functions.
The A-549 cell line originates from a lung adenocarcinoma of a 58-year-old Caucasian male and serves as a model for human alveolar type II pneumocytes and lung adenocarcinoma. These epithelial cells retain features relevant to pulmonary biology and cancer, including tumorigenic potential and expression of lineage markers. Genetic disruption of IL18 in this background provides a targeted tool to analyze cytokine-mediated processes in lung epithelial cells.
Interleukin-18 (IL18) is a proinflammatory cytokine central to innate and adaptive immunity. It requires proteolytic activation by caspase-1 within NLRP3 or AIM2 inflammasomes, triggered by upstream regulators such as TLR ligands, LPS, TNF-alpha, and IFN-gamma. Secreted IL18 binds to its heterodimeric receptor IL18R1/IL18RAP, recruiting MyD88 and initiating signaling via IRAK4, IRAK1, and TRAF6 to activate NF-kB and MAPKs. This signaling cascade drives transcription of downstream targets including IFN-gamma, TNF-alpha, IL-13, IL-4, IL-8, and chemokines, and contributes to Th1 and Th2 differentiation. The pathway is tempered by the decoy receptor IL18BP. Disruption of IL18 in this knockout model thus eliminates ligand-dependent signaling through the IL18 receptor complex.
Within A-549 lung epithelial cells, IL18 signaling is pertinent to pulmonary inflammation, tumor-immune interactions, and the cancer microenvironment. These cells can produce and respond to IL18, influencing immune cell recruitment and metastatic behavior. The IL18 knockout thus enables dissection of autocrine and paracrine inflammatory loops and examination of how loss of epithelial IL18 alters downstream effector expression and co-culture interactions. Furthermore, since A-549 cells express inflammasome components, this model facilitates study of the intersection between inflammasome activation and IL18-mediated oncogenic processes.
Researchers can employ this knockout model in diverse experimental settings, including analysis of IL18-dependent signaling in lung cancer, tumor microenvironment studies, inflammasome biology, and immune checkpoint regulation. Representative applications involve techniques such as western blotting, RT-qPCR, ELISA, flow cytometry, NF-kB reporter assays, co-immunoprecipitation, migration/invasion assays, and drug sensitivity testing for pathway inhibitors. For further details or to discuss customization, contact Ascent Research.
